Nvidia CEO Jensen Huang says the company will take a minority stake in France’s Doctolib

Nvidia plans to take a minority stake in Doctolib, a French medical website used by patients and health professionals, Nvidia chief executive Jensen Huang said Tuesday. Huang framed the move as part of a broader effort to apply Nvidia technology to health care, including ways to improve how care is delivered and coordinated through digital tools.

The comments came as Nvidia continues to position its chips and AI software beyond traditional tech and into industries that use large amounts of data. In Huang’s remarks, Doctolib was described as the vehicle for putting that technology to work in a real-world health setting rather than as a standalone investment.

Doctolib operates a platform where patients search for appointments and health professionals manage scheduling and related administrative tasks. The company’s stated plan, as characterized by Huang, is to use technology to improve health care, suggesting the investment is intended to support product development that benefits the platform’s users and care providers.

The amount of the planned stake was not included in the available report, and Nvidia did not describe any specific deal terms in the brief account. It was also not disclosed what types of Nvidia products or services would be used, such as whether the arrangement would center on AI infrastructure, software, or other technology tailored for medical use cases.

For Nvidia, health care has increasingly become an adjacent market to its core data center and AI computing businesses. By linking its technology to a high-volume, appointment-driven digital health platform, Nvidia is effectively exploring how AI workloads and data processing could be integrated into operational workflows where speed and reliability matter.

For Doctolib, partnering with a major AI chip supplier would align with a strategy that depends on improving user experiences and operational efficiency. Although the report did not provide details about the timing of the technology rollout or specific performance goals, the investment indicates that Doctolib is seeking to strengthen its platform’s capabilities with AI.

Even with Huang’s confirmation of a planned minority stake, several key questions remain unanswered in the public account. The report did not specify the ownership percentage, the valuation, the expected closing timeline, or whether either company is targeting particular health-care functions such as scheduling optimization, clinical workflows, patient engagement, or other functions.

Investors and competitors will likely watch for follow-up disclosure on deal structure and technology scope, as well as any measurable changes to Doctolib’s product roadmap. For Nvidia, the Doctolib partnership also underscores how it may pursue additional industry integrations as AI adoption spreads into sectors beyond software and cloud computing.